ME  Vol.5 No.5 , May 2014
Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines—Part II
ABSTRACT

The objective of this analysis is to build a regression cost model towards the data for budget expenditures for rare diseases in Bulgaria and to evaluate the future impact on the health care budget. Four regression cost models were built based on previously published results of the macro costing top down financial analysis of the expenditures for medicines spent by the 3rd party payer. In Bulgaria that is the national health insurance fund (NHIF). The previous analysis covers the period 2010-2013 year and the regression models are forecasting the future expenditures till 2016 year. Four models follow linear regression among the researched variables and expected future changes. The cost of all reimbursed medicines, dietary food and medical devices is expected to reach 703 million of BGN, medicines expenditures are expected to reach 680 million, number of reimbursed medicines is expected to be 2315, and expenditures for rare diseases will reach 96 million of BGN. The number of patients, as well as the budget allocated for orphan drugs is increasing in time, with the addition of the critical fact that the oncology drugs were transferred to the NHIF. This is a positive result based on a number of factors, but also reveals the importance of carefully predicting and allocating the funds needed for orphan drugs. The model analyzing costs for pharmacotherapy shows that these expenses will increase linearly in the next three years, which in turn will put the financial capabilities of the NHIF to the test, as well as limit the access of patients to orphan drugs.


Cite this paper
Zlatareva, A. , Tachkov, K. , Stoicheva, M. , Georgieva, S. , Bozhkova, M. and Petrova, G. (2014) Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines—Part II. Modern Economy, 5, 499-505. doi: 10.4236/me.2014.55047.
References
[1]   Ministry of Health (2012) National Program for Rare Diseases.
www.rare-bg.com/wp-content/uploads/2013/01/NPRD_2009-20131.doc

[2]   EC (2007) Rare Diseases Challenge for the Society.
www.ec.europa.eu/health/archive/ph_threats/non_com/docs/raredis_comm_bg.pdf

[3]   Zlatareva, A., Tachkov, K., Stoicheva, M., Georgieva, S., Momekov, G. and Petrova, G. (2014) Financial Analysis of the Access to Pharmacotherapy for Rare Diseases in Bulgaria. Modern Economy, Submitted for Publication.

[4]   Georgieva, S., Petrova, G., Dimitrova, M., Peikova, L., Paskalev, E., Filipov, J. and Zlatkov, B. (2013) Prospective Study of the Changes in Pharmacotherapy Cost of Adult Kidney Transplant Patients in Bulgaria. Modern Economy, 4, 827-831.
http://dx.doi.org/10.4236/me.2013.412089

[5]   Schey, C., Milanova, T. and Hutchings, A. (2011) Estimating the Budget Impact of Orphan Medicines in Europe: 2010-2020. Orphanet Journal of Rare Diseases, 27, 62.
http://dx.doi.org/10.1186/1750-1172-6-62

[6]   Savova, A., Kamusheva, M., Georgieva, S., Stoimenova, A. and Petrova, G. (2013) Budget Impact Analysis of Chronic Myeloid Leukemia Treatment in Bulgaria. Biotechnology and Biotechnology Equipment, 27, 3595-3598.
http://dx.doi.org/10.5504/BBEQ.2012.0075

[7]   Field, M. and Boat, T. (2010) Rare Diseases and Orphan Products: Accelerating Research and Development. National Academies Press, Washington DC.

[8]   Kamusheva, M., Stoimenova, A., Doneva, M., Zlatareva, A. and Petrova, G. (2013) A Cross Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece, Macedonia. Biotechnology and Biotechnology Equipment, 27, 4186-4193.
http://dx.doi.org/10.5504/BBEQ.2013.0066

[9]   Zlatareva, A., Lakic, D., Kamusheva, M., Spaskov, D., Momekov, G. and Petrova, G. (2013) Analysis of Access to Orphan Drugs in Five Neighboring European Countries—Bulgaria, Greece, Macedonia, Romania and Serbia. World Journal of Pharmacy and Pharmaceutical Sciences, 2, 2278-4357.

[10]   O’Sullivan, A. (2012) Should Orphan Drugs Be Subjected to Value-Based Assessments. 17th Annual Meeting of International Society of Pharmacoeconomics & Outcomes Research, 4 June 2012.
http://www.ispor.org/meetings/WashingtonDC0512/releasedpresentations/IP5-Sullivan.pdf

[11]   Simoens, S. (2011) Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency. Orphanet Journal of Rare Diseases, 6, 42.
http://dx.doi.org/10.1186/1750-1172-6-42

[12]   Inotai, A., Petrova, G., Vitezic, D. and Kaló, Z. (2014) Benefits of Investment into Modern Medicines in Central-Eastern European Countries. Experts Review of Pharmacoeconomics and Outcomes Research, 14, 71-79.
http://dx.doi.org/10.1586/14737167.2014.868314

[13]   Kanavos, P., et al. (2011) Differences in Costs of and Access to Pharmaceutical Products in the EU. Directorate-General for Internal Policies, European Parliament.
http://www.lse.ac.uk/businessAndconsultancy/LSEConsulting/pdf/pharmaceuticals.pdf

[14]   Bignami, F. (2007) Eurordis Survey on Orphan Drugs Availability in Europe. Presented at the 6th Eurordis Round Table of Companies Workshop, Barcelona.
http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf

[15]   MH (2009) National Council for Rare Diseases.
http://www.mh.government.bg/Articles.aspx?lang=bg-BG&pageid=476

[16]   Carone, G., Schwierz, C. and Xavier, A. (2012) Cost-Containment Policies in Public Pharmaceutical Spending in the EU. European Commission, Directorate General for Economic and Financial Affairs.
www.ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf

[17]   Massol, J., Puech, A. and Boissel, J.-P. (2007) How to Anticipate the Assessment of the Public Health Benefit of New Medicines? Therapie, 62, 427-435.
http://dx.doi.org/10.2515/therapie:2007071

 
 
Top